⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVL News
Nuvalent, Inc. Class A Common Stock
Nuvalent Announces Pricing of Public Offering of Common Stock
prnewswire.com
NUVL
Nuvalent Announces Public Offering of Common Stock
prnewswire.com
NUVL
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
prnewswire.com
NUVL
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
prnewswire.com
NUVL
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
prnewswire.com
NUVL
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
prnewswire.com
NUVL
NUVL
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
prnewswire.com
NUVL
NUVL
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
prnewswire.com
NUVL
NUVL
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
prnewswire.com
NUVL
NUVL